Expand all sections

Lubiprostone

Amitiza

Extended indication

Functional constipation in children.
Therapeutic value

No judgement

Product

Active substance

Lubiprostone
Domain

Metabolism and Endocrinology
Main indication

Bowel diseases
Extended indication

Functional constipation in children.
Proprietary name

Amitiza
Manufacturer

Takeda
Additional remarks 
November 2017: Fabrikant geeft aan dat product niet op de Nederlandse markt komt.

Registration

There is currently nothing known about registration.

Therapeutic value

Therapeutic value

No judgement
Duration of treatment

Not found

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.